Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2001 2
2003 9
2004 1
2005 4
2006 5
2007 5
2008 3
2009 7
2010 6
2011 6
2012 3
2013 10
2014 13
2015 20
2016 21
2017 16
2018 13
2019 23
2020 29
2021 31
2022 29
2023 31
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

254 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3.
Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, Blodi BA, Bottoni F, Chakravarthy U, Chew EY, Csaky K, Danis RP, Fleckenstein M, Freund KB, Grunwald J, Hoyng CB, Jaffe GJ, Liakopoulos S, Monés JM, Pauleikhoff D, Rosenfeld PJ, Sarraf D, Spaide RF, Tadayoni R, Tufail A, Wolf S, Staurenghi G. Sadda SR, et al. Among authors: tadayoni r. Ophthalmology. 2018 Apr;125(4):537-548. doi: 10.1016/j.ophtha.2017.09.028. Epub 2017 Nov 2. Ophthalmology. 2018. PMID: 29103793 Free article.
Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group.
Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, Waheed NK, Chakravarthy U, Rosenfeld PJ, Holz FG, Souied EH, Cohen SY, Querques G, Ohno-Matsui K, Boyer D, Gaudric A, Blodi B, Baumal CR, Li X, Coscas GJ, Brucker A, Singerman L, Luthert P, Schmitz-Valckenberg S, Schmidt-Erfurth U, Grossniklaus HE, Wilson DJ, Guymer R, Yannuzzi LA, Chew EY, Csaky K, Monés JM, Pauleikhoff D, Tadayoni R, Fujimoto J. Spaide RF, et al. Among authors: tadayoni r. Ophthalmology. 2020 May;127(5):616-636. doi: 10.1016/j.ophtha.2019.11.004. Epub 2019 Nov 14. Ophthalmology. 2020. PMID: 31864668 Free article.
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Among authors: tadayoni r. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Reply.
Bousquet E, Dhundass M, Lejoyeux R, Shinojima A, Krivosic V, Mrejen S, Gaudric A, Tadayoni R. Bousquet E, et al. Among authors: tadayoni r. Am J Ophthalmol. 2019 Jul;203:120-121. doi: 10.1016/j.ajo.2019.02.021. Epub 2019 Jun 10. Am J Ophthalmol. 2019. PMID: 31196567 No abstract available.
Optical coherence tomography-based consensus definition for lamellar macular hole.
Hubschman JP, Govetto A, Spaide RF, Schumann R, Steel D, Figueroa MS, Sebag J, Gaudric A, Staurenghi G, Haritoglou C, Kadonosono K, Thompson JT, Chang S, Bottoni F, Tadayoni R. Hubschman JP, et al. Among authors: tadayoni r. Br J Ophthalmol. 2020 Dec;104(12):1741-1747. doi: 10.1136/bjophthalmol-2019-315432. Epub 2020 Feb 27. Br J Ophthalmol. 2020. PMID: 32107208 Review.
Reply.
Couturier A, Lavia C, Gaudric A, Tadayoni R. Couturier A, et al. Among authors: tadayoni r. Ophthalmology. 2020 May;127(5):e34-e35. doi: 10.1016/j.ophtha.2020.01.002. Ophthalmology. 2020. PMID: 32327142 No abstract available.
KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.
Brown DM, Emanuelli A, Bandello F, Barranco JJE, Figueira J, Souied E, Wolf S, Gupta V, Ngah NF, Liew G, Tuli R, Tadayoni R, Dhoot D, Wang L, Bouillaud E, Wang Y, Kovacic L, Guerard N, Garweg JG. Brown DM, et al. Among authors: tadayoni r. Am J Ophthalmol. 2022 Jun;238:157-172. doi: 10.1016/j.ajo.2022.01.004. Epub 2022 Jan 14. Am J Ophthalmol. 2022. PMID: 35038415 Free article. Clinical Trial.
Non-vasogenic cystoid maculopathies.
Gaudric A, Audo I, Vignal C, Couturier A, Boulanger-Scemama É, Tadayoni R, Cohen SY. Gaudric A, et al. Among authors: tadayoni r. Prog Retin Eye Res. 2022 Nov;91:101092. doi: 10.1016/j.preteyeres.2022.101092. Epub 2022 Aug 1. Prog Retin Eye Res. 2022. PMID: 35927124 Free article. Review.
254 results